Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)
Authors
Alexander Reichart
Dirk Jäger
Christoph Springfeld (ORCID: https://orcid.org/0000-0003-3843-101X)
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)
Alexander Reichart, Dirk Jäger, Christoph Springfeld, Leonie Jochheim et al.
Citations
3 citations
Journal
BMJ Open
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
3.14
article
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)
Alexander Reichart, Dirk Jäger, Christoph Springfeld, Leonie Jochheim, Patrick Michl, Michael T. Dill, Pavlos Missios, Conrad Rauber, Lukas D. Sauer, Thomas J. Ettrich, Anastasia Tsakmaklis, Peter Schirmacher, Raphael Mohr, Arne Kandulski, Maria J. G. T. Vehreschild, María Paula Roberti, Anja Sander, Andreas Teufel, Dirk Waldschmidt
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
BMJ OpenVol. 15(9)
Institutions
Goethe University Frankfurt (DE), German Cancer Research Center (DE), University of Cologne (DE), Heidelberg University (DE), University Hospital Augsburg (DE), University Hospital Heidelberg (DE), University Hospital Regensburg (DE), National Center for Tumor Diseases (DE), German Center for Infection Research (DE), Hopp Children's Cancer Center Heidelberg (DE), University Children's Hospital Tübingen (DE), University Hospital Frankfurt (DE), University Hospital Cologne (DE), University Hospital Ulm (DE), University Medical Centre Mannheim (DE), University of Duisburg-Essen (DE), Charité - Universitätsmedizin Berlin (DE)